Skip to content
Homepage
Author:
Calidi Biotherapeutics, Inc
Posted Date:
March 27, 2026
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics, Inc
March 27, 2026
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials
Calidi Biotherapeutics, Inc
March 24, 2026
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
Calidi Biotherapeutics, Inc
March 12, 2026
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
Calidi Biotherapeutics, Inc
March 9, 2026
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
Calidi Biotherapeutics, Inc
March 6, 2026
Calidi Biotherapeutics Announces Proposed Public Offering
Calidi Biotherapeutics, Inc
March 5, 2026
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
Calidi Biotherapeutics, Inc
February 20, 2026
Prev
1
2
3
